Fluidosomes tobramycin regulatory update

FDA granted Orphan Drug designation for Axentis' Fluidsomes tobramycin to treat pulmonary infections caused by Burkholderia cepacia in patients with cystic fibrosis (CF). The inhalable liposomal formu...